## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.4% below STRENGTH zone (3.0-6.0%); PEG 4.00 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($651.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. What to Expect From IDEXX Laboratoriesâ€™ Next Quarterly Earnings Report?**
- Source: inkl | 20260105T160819 | Bullish | Relevance: 100%
- IDEXX Laboratories (IDXX) is a multinational healthcare company specializing in diagnostics for animal care and water quality. Analysts anticipate the company will report a profit of $2.93 per share for fiscal Q4 2025, an 11.8% increase year-over-year. The company has consistently exceeded Wall Street's earnings estimates in the past four quarters, and its stock has significantly outperformed the S&P 500 and Health Care Select Sector SPDR Fund over the past year.

**2. IDEXX Laboratories, Inc. $IDXX Shares Acquired by Allspring Global Investments Holdings LLC**
- Source: MarketBeat | 20260104T085304 | Bullish | Relevance: 100%
- Allspring Global Investments Holdings LLC significantly increased its stake in IDEXX Laboratories, Inc. by 1,165.7% in Q3, now owning 46,489 shares valued at $28.83 million. This comes as insider Nimrata Hunt sold a substantial portion of her shares. Analysts have raised price targets for IDEXX, which maintains a "Moderate Buy" consensus rating after beating quarterly earnings and revenue expectations.

**3. IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Recommendation of "Moderate Buy" from Brokerages**
- Source: MarketBeat | 20260103T064745 | Bullish | Relevance: 100%
- IDEXX Laboratories, Inc. (NASDAQ:IDXX) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $763.50. This comes after the company reported strong quarterly earnings, beating analyst expectations, and provided upbeat guidance for FY2025. Despite a premium valuation with a P/E ratio of 53.13, analysts have reiterated "buy" and "overweight" ratings, signaling continued confidence in the animal health diagnostics provider.

**4. IDEXX Laboratories: How a Quiet Diagnostics Giant Is Rewriting the Future of Animal Health**
- Source: AD HOC NEWS | 20260104T060839 | Bullish | Relevance: 100%
- IDEXX Laboratories has transformed veterinary diagnostics into a high-margin, high-tech platform business by integrating in-clinic analyzers, reference lab services, software, and AI tools. This ecosystem approach provides a unified workflow for veterinary practices and addresses the rising demand for sophisticated animal healthcare amidst workforce shortages. The company's unique selling proposition lies in its data and AI capabilities, workflow integration, and recurring revenue model, contributing to its strong market valuation and competitive edge against rivals like Zoetis and Antech Diagnostics.

**5. IDEXX Laboratories (NASDAQ:IDXX) Upgraded at Wall Street Zen**
- Source: MarketBeat | 20260103T062745 | Bullish | Relevance: 99%
- Wall Street Zen has upgraded IDEXX Laboratories (NASDAQ:IDXX) from a "buy" to a "strong-buy" rating, reflecting a generally bullish outlook with an average price target of $763.50. The company recently surpassed earnings expectations with an EPS of $3.22 and revenue of $1.11 billion, prompting a positive FY2025 guidance. Despite a significant insider stock sale, institutional investors hold a substantial stake in the animal healthcare diagnostic firm.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.0x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.00 signals overvaluation risk, limited margin of safety. Forward P/E 47.3x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.6B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.00 |
| Forward P/E | 47.3 |
| Current P/E | 52.9 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.6% to -0.4% (+1.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-3.05), momentum weakening. RSI neutral at 44. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.42% (CS: 33) | Neutral |
| RSI_14 | 43.9 | Neutral |
| MACD Histogram | -3.05 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.979x | Below |
| vs SMA200 | 1.168x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $682.23
- **Stop Loss:** $651.31 (4.5% risk)
- **Target:** $713.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $18,420.21
- **Portfolio %:** 18.42%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*